Finding 979993 (2023-001)

Significant Deficiency
Requirement
H
Questioned Costs
$1
Year
2023
Accepted
2024-06-27
Audit: 310598
Organization: City of Hope (CA)

AI Summary

  • Core Issue: Internal controls were ineffective, leading to noncompliance with federal requirements for liquidating financial obligations within 120 days post-performance period.
  • Impacted Requirements: Violations of Title 2, Part 200.303 (internal controls) and Part 200.344 (closeout) regarding timely liquidation of federal award obligations.
  • Recommended Follow-Up: Management should implement stronger internal controls and refund the questioned costs of $5,227 to ensure compliance moving forward.

Finding Text

Internal control deficiency and noncompliance over Period of Performance. Identification of the federal program: Research and Development Cluster See the Schedule of Findings and Questioned Costs for table. Criteria or specific requirement (including statutory, regulatory or other citation): Title 2, Subtitle A, Chapter II, Part 200, Subpart D, 200.303 – Internal controls. The non-Federal entity must: (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Title 2, Subtitle A, Chapter II, Part 200, Subpart D, 200.344 – Closeout. The Federal awarding agency or pass-through entity will close out the Federal award when it determines that all applicable administrative actions and all required work on the Federal award have been completed by the non-Federal entity. If the non-Federal entity fails to complete the requirements, the Federal awarding agency or pass-through entity will proceed to close out the Federal award with the information available. This section specifies the actions the non-Federal entity and Federal awarding agency or pass-through entity must take to complete this process at the end of the period of performance: (b) Unless the Federal awarding agency or pass-through entity authorizes an extension, a non-Federal entity must liquidate all financial obligations incurred under the Federal award no later than 120 calendar days after the end date of the period of performance as specified in the terms and conditions of the Federal award. Condition: During our testing over period of performance, we observed management did not have effective internal controls in place to ensure all financial obligations incurred were liquidated under the Federal award no later than 120 calendar days after the end date of the period of performance as specified in the terms and conditions of the Federal award. Cause: Management did not have effective internal controls in place over the compliance requirement as stated in the criteria or specific requirement section above. Effect or potential effect: Management was reimbursed from the grantor for financial obligations incurred that were not liquidated under the Federal award no later than 120 calendar days after the end date of the period of performance as specified in the terms and conditions of the Federal award. Questioned costs: $5,227 – Assistance Listing Number 93.394, Award Identification Number – 7 R01 CA184792 Questioned costs were computed by taking the total financial obligations incurred that were not liquidated under the Federal award no later than 120 calendar days after the end date of the period of performance as specified in the terms and conditions of the Federal award. Context: Testing over period of performance were performed over City of Hope and Translational Genomics Research Institute separately with respect to internal controls as they operate under different internal control environments and combined with respect to compliance. During our testing over period of performance, we obtained a listing of federal awards with performance period ending dates during the audit period and tested transactions for federal award costs to verify that the liquidation occurred within the allowed time period. We selected a compliance sample of 26 (23 samples for City of Hope and 3 samples for Translational Genomics Research Institute). The total value of the 23 samples for City of Hope was $223,159 and the total value of the 3 samples for Translational Genomics Research Institute was $3,733. The questioned costs were found within the City of Hope samples. The total population subjected to testing for City of Hope was $4,615,052. There was 1 ($5,227) out of 23 ($223,159) samples where management was reimbursed from the grantor for a financial obligation incurred that was not liquidated under the Federal award no later than 120 calendar days after the end date of the period of performance as specified in the terms and conditions of the Federal award. Identification as a repeat finding, if applicable: No. Recommendation: We recommend that management develop and implement effective internal controls to ensure all financial obligations incurred were liquidated under the Federal award no later than 120 calendar days after the end date of the period of performance as specified in the terms and conditions of the Federal award. In addition, management should refund the questioned costs. Views of responsible officials: In response to this finding City of Hope (COH) will complete the following: 1. Research Accounting will present finding and revisit guidelines on period of performance requirements with Research and Post Award Accounting personnel. 2. COH will refund the identified questioned costs.

Categories

Questioned Costs Internal Control / Segregation of Duties Period of Performance Subrecipient Monitoring

Other Findings in this Audit

  • 403506 2023-001
    Significant Deficiency
  • 403507 2023-001
    Significant Deficiency
  • 403508 2023-001
    Significant Deficiency
  • 403509 2023-001
    Significant Deficiency
  • 403510 2023-001
    Significant Deficiency
  • 403511 2023-001
    Significant Deficiency
  • 403512 2023-001
    Significant Deficiency
  • 403513 2023-001
    Significant Deficiency
  • 403514 2023-001
    Significant Deficiency
  • 403515 2023-001
    Significant Deficiency
  • 403516 2023-001
    Significant Deficiency
  • 403517 2023-001
    Significant Deficiency
  • 403518 2023-001
    Significant Deficiency
  • 403519 2023-001
    Significant Deficiency
  • 403520 2023-002
    Significant Deficiency Repeat
  • 403521 2023-001
    Significant Deficiency
  • 403522 2023-001
    Significant Deficiency
  • 403523 2023-001
    Significant Deficiency
  • 403524 2023-001
    Significant Deficiency
  • 403525 2023-002
    Significant Deficiency Repeat
  • 403526 2023-001
    Significant Deficiency
  • 403527 2023-001
    Significant Deficiency
  • 403528 2023-001
    Significant Deficiency
  • 403529 2023-001
    Significant Deficiency
  • 403530 2023-001
    Significant Deficiency
  • 403531 2023-002
    Significant Deficiency Repeat
  • 403532 2023-001
    Significant Deficiency
  • 403533 2023-001
    Significant Deficiency
  • 403534 2023-001
    Significant Deficiency
  • 403535 2023-002
    Significant Deficiency Repeat
  • 403536 2023-001
    Significant Deficiency
  • 403537 2023-001
    Significant Deficiency
  • 403538 2023-002
    Significant Deficiency Repeat
  • 403539 2023-001
    Significant Deficiency
  • 403540 2023-001
    Significant Deficiency
  • 403541 2023-001
    Significant Deficiency
  • 403542 2023-001
    Significant Deficiency
  • 403543 2023-001
    Significant Deficiency
  • 403544 2023-001
    Significant Deficiency
  • 403545 2023-001
    Significant Deficiency
  • 403546 2023-001
    Significant Deficiency
  • 403547 2023-002
    Significant Deficiency Repeat
  • 403548 2023-001
    Significant Deficiency
  • 403549 2023-002
    Significant Deficiency Repeat
  • 403550 2023-001
    Significant Deficiency
  • 403551 2023-001
    Significant Deficiency
  • 403552 2023-002
    Significant Deficiency Repeat
  • 403553 2023-001
    Significant Deficiency
  • 403554 2023-001
    Significant Deficiency
  • 403555 2023-001
    Significant Deficiency
  • 403556 2023-001
    Significant Deficiency
  • 403557 2023-001
    Significant Deficiency
  • 403558 2023-001
    Significant Deficiency
  • 403559 2023-001
    Significant Deficiency
  • 403560 2023-001
    Significant Deficiency
  • 403561 2023-001
    Significant Deficiency
  • 403562 2023-001
    Significant Deficiency
  • 403563 2023-002
    Significant Deficiency Repeat
  • 403564 2023-001
    Significant Deficiency
  • 403565 2023-001
    Significant Deficiency
  • 403566 2023-002
    Significant Deficiency Repeat
  • 403567 2023-001
    Significant Deficiency
  • 403568 2023-001
    Significant Deficiency
  • 403569 2023-001
    Significant Deficiency
  • 403570 2023-001
    Significant Deficiency
  • 403571 2023-001
    Significant Deficiency
  • 403572 2023-002
    Significant Deficiency Repeat
  • 403573 2023-001
    Significant Deficiency
  • 403574 2023-001
    Significant Deficiency
  • 403575 2023-001
    Significant Deficiency
  • 979948 2023-001
    Significant Deficiency
  • 979949 2023-001
    Significant Deficiency
  • 979950 2023-001
    Significant Deficiency
  • 979951 2023-001
    Significant Deficiency
  • 979952 2023-001
    Significant Deficiency
  • 979953 2023-001
    Significant Deficiency
  • 979954 2023-001
    Significant Deficiency
  • 979955 2023-001
    Significant Deficiency
  • 979956 2023-001
    Significant Deficiency
  • 979957 2023-001
    Significant Deficiency
  • 979958 2023-001
    Significant Deficiency
  • 979959 2023-001
    Significant Deficiency
  • 979960 2023-001
    Significant Deficiency
  • 979961 2023-001
    Significant Deficiency
  • 979962 2023-002
    Significant Deficiency Repeat
  • 979963 2023-001
    Significant Deficiency
  • 979964 2023-001
    Significant Deficiency
  • 979965 2023-001
    Significant Deficiency
  • 979966 2023-001
    Significant Deficiency
  • 979967 2023-002
    Significant Deficiency Repeat
  • 979968 2023-001
    Significant Deficiency
  • 979969 2023-001
    Significant Deficiency
  • 979970 2023-001
    Significant Deficiency
  • 979971 2023-001
    Significant Deficiency
  • 979972 2023-001
    Significant Deficiency
  • 979973 2023-002
    Significant Deficiency Repeat
  • 979974 2023-001
    Significant Deficiency
  • 979975 2023-001
    Significant Deficiency
  • 979976 2023-001
    Significant Deficiency
  • 979977 2023-002
    Significant Deficiency Repeat
  • 979978 2023-001
    Significant Deficiency
  • 979979 2023-001
    Significant Deficiency
  • 979980 2023-002
    Significant Deficiency Repeat
  • 979981 2023-001
    Significant Deficiency
  • 979982 2023-001
    Significant Deficiency
  • 979983 2023-001
    Significant Deficiency
  • 979984 2023-001
    Significant Deficiency
  • 979985 2023-001
    Significant Deficiency
  • 979986 2023-001
    Significant Deficiency
  • 979987 2023-001
    Significant Deficiency
  • 979988 2023-001
    Significant Deficiency
  • 979989 2023-002
    Significant Deficiency Repeat
  • 979990 2023-001
    Significant Deficiency
  • 979991 2023-002
    Significant Deficiency Repeat
  • 979992 2023-001
    Significant Deficiency
  • 979994 2023-002
    Significant Deficiency Repeat
  • 979995 2023-001
    Significant Deficiency
  • 979996 2023-001
    Significant Deficiency
  • 979997 2023-001
    Significant Deficiency
  • 979998 2023-001
    Significant Deficiency
  • 979999 2023-001
    Significant Deficiency
  • 980000 2023-001
    Significant Deficiency
  • 980001 2023-001
    Significant Deficiency
  • 980002 2023-001
    Significant Deficiency
  • 980003 2023-001
    Significant Deficiency
  • 980004 2023-001
    Significant Deficiency
  • 980005 2023-002
    Significant Deficiency Repeat
  • 980006 2023-001
    Significant Deficiency
  • 980007 2023-001
    Significant Deficiency
  • 980008 2023-002
    Significant Deficiency Repeat
  • 980009 2023-001
    Significant Deficiency
  • 980010 2023-001
    Significant Deficiency
  • 980011 2023-001
    Significant Deficiency
  • 980012 2023-001
    Significant Deficiency
  • 980013 2023-001
    Significant Deficiency
  • 980014 2023-002
    Significant Deficiency Repeat
  • 980015 2023-001
    Significant Deficiency
  • 980016 2023-001
    Significant Deficiency
  • 980017 2023-001
    Significant Deficiency

Programs in Audit

ALN Program Name Expenditures
93.498 Covid-19 - Provider Relief Fund and American Rescue Plan (arp) Rural Distribution $12.63M
97.036 Covid-19 - Disaster Grants - Public Assistance (presidentially Declared Disasters) $11.34M
93.172 Human Genome Research $1.13M
93.113 Environmental Health $973,111
93.493 Congressional Directives $602,039
21.027 Covid-19 - Coronavirus State and Local Fiscal Recovery Funds $322,083
93.837 Cardiovascular Diseases Research $291,657
12.420 Military Medical Research and Development $258,239
93.310 Trans-Nih Research Support $257,239
93.242 Mental Health Research Grants $247,747
93.173 Research Related to Deafness and Communication Disorders $202,409
93.859 Biomedical Research and Research Training $194,967
93.383 Public Health Nursing $177,748
93.273 Alcohol Research Programs $175,444
93.397 Cancer Centers Support Grants $175,023
93.394 Cancer Detection and Diagnosis Research $174,342
93.867 Vision Research $131,454
10.025 Plant and Animal Disease, Pest Control, and Animal Care $131,096
93.396 Cancer Biology Research $130,675
93.866 Aging Research $128,795
93.084 Prevention of Disease, Disability, and Death by Infectious Diseases $110,526
93.361 Nursing Research $103,925
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $96,038
93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health $81,703
93.226 Research on Healthcare Costs, Quality and Outcomes $76,209
93.393 Cancer Cause and Prevention Research $74,063
93.399 Cancer Control $67,140
93.398 Cancer Research Manpower $54,322
93.389 National Center for Research Resources $36,907
10.310 Agriculture and Food Research Initiative (afri) $30,236
93.395 Cancer Treatment Research $28,262
10.001 Agricultural Research Basic and Applied Research $25,148
93.307 Minority Health and Health Disparities Research $23,992
93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders $10,532
93.838 Lung Diseases Research $8,923
93.839 Blood Diseases and Resources Research $4,802
32.006 Covid-19 - Covid-19 Telehealth Program $2,696
93.353 21st Century Cures Act - Beau Biden Cancer Moonshot $2,534
93.879 Medical Library Assistance $1,500
93.103 Food and Drug Administration Research $405
93.855 Allergy and Infectious Diseases Research $248
93.865 Child Health and Human Development Extramural Research $-246
93.121 Oral Diseases and Disorders Research $-8,726